Vitamin market in most regions stable and calm

Both vitamin A and E seem to have stabilised. But for vitamin E, buyers are still looking at concluding longer term contracts as they feel there is limited potential downwards. For vitamin A that is not the case. Vitamin C suppliers returned to the market last week, after being absent for some months, but their offers disappeared as quickly as they came. Most of them have stopped offering again. The rest of the vitamin market is not really moving at this moment and no major events expected either.

In partnership with Feed Additive Prices

Vitamin E 50%

Mixed signals in the market. Some market participants indicate that there is poor availability for nearby and for Q2, while others say that the situation has improved compared to some weeks ago. Overall there seems to be a consensus that the price will not go down much further in the coming period and that has led to forward cover well into Q2 and in some cases buyers are also interested to look even further ahead. In most regions, things seem to be calmer now, and also in the US things have cooled down a bit it seems. No immediate impact on the market has been seen so far, after the announcement of one of the main manufacturers to sell their animal health business, including vitamins. Q1 is contracted and a good portion of Q2 is as well.

Vitamin A 1000

The market has stabilised again, after a recent small price increase. The spot market even showed a small price decline in Europe and China as new demand is currently almost absent. Recently, one of the main vitamin A1000 manufacturers has announced to sell of their vitamin business. So far, that has not impacted the short-term market. Availability is still said to be tight. A portion of Q2 has been contracted by now.

Vitamin D3 500

Compared to last week, no new activity is seen really. The market is calm and prices seem to be stable in most regions. Recently, when prices became low and container shipments started to be disrupted ex China, buyers decided to take some forward cover. Stock levels in the regions are said to be OK/limited. Q1 is contracted and some Q2 volumes are as well.

Vitamin B2 80%

A very static market and no news or significant changes are to be reported. The vitamin B2 market is very quiet and stable. Prices in Asia are still relatively low, while prices in Europe are higher and stable and in the US as well, compared to that. A portion of Q2 is contracted.

D-Calpan

At least at this moment, it seems the price decline has stopped and the market has bottomed out at a very low level. Very quiet market at the moment and already decent cover ahead is taken, as buyers estimated risks and the chance of even lower prices and wanted to secure some supply. Reasonable cover is taken into Q2. For the longer term, there is still a wait-and-see attitude.

Vitamin B3

Availability seems to be good, especially since China is supplying an ample volume of vitamin B3. Despite the strong desire from suppliers to increase the price, which succeeded some time ago, the market has become more stable now again at a low level. Forward cover into Q2 has been taken recently and currently, there is no additional demand seen in most regions. Overall, it is relatively quiet and there is already decent cover for Q1 and into Q2.

Biotin

For quite some time there have been no significant changes in the market, although lately there has been some slight price decline again. Prices remain historically low and supply is ample. A portion of Q2 is contracted by now. In some cases, buyers took long-term contracts well into 2024, some of them also older contracts.

Vitamin C 35% mono

Several suppliers returned to the market recently, after having been absent for some months. But quite quickly, a lot of those offers were gone again and several suppliers went back to their non-offering status. The price offers that are still out there, are in line with the higher market prices of the previous period. Most buyers took long-term contracts when the price was low or when it started to increase. Q1 and Q2 are mostly contracted and in some cases a large portion of 2024 as well.